Search results
Vlad II ( Romanian: Vlad al II-lea ), also known as Vlad Dracul ( Vlad al II-lea Dracul) or Vlad the Dragon (before 1395 – November 1447), was Voivode of Wallachia from 1436 to 1442, and again from 1443 to 1447. He is internationally known as the father of Vlad the Impaler, or Dracula. Born an illegitimate son of Mircea I of Wallachia, he ...
- 1436 – 1442
- Eastern Orthodox
Source citation. Prince of Wallachia, also known as Vlad III, Vlad the Impaler, Vlad Dracula, or Vlad Tepes. Born between 1428 and 1431, the second of four sons of Eupraxia of Moldavia and Vlad II Dracul of Wallachia. In 1442, he accompanied his father and brother, Radu, on a diplomatic mission. The three were captured, but Vlad II...
Vlad III was born sometime between 1428 and 1431, presumably after his father, Vlad II settled in Transylvania. According to most historians, his mother was either a daughter (Princess Cneajna of Moldavia) or a kinswoman (Eupraxia of Moldavia) of Alexander I of Moldavia and the first wife of his father.
The Life of St Eupraxia of Tabenna is a detailed account of the life and deeds of one of the first Egyptian desert mothers, who entered a desert convent as a child and spent her life in ascetic deeds. Though St Eupraxia does not count among the most popular and widely known women saints within the Byzantine world, as a regular ‘model nun ...
Jul 24, 2015 · St Eupraxia. Posted on 24/07/2015. Antigonus and his wife Eupraxia were pious and bestowed generous alms on the destitute. A daughter was born to them, whom they also named Eupraxia. Antigonos soon died, and the mother withdrew from the imperial court. She went with her daughter to Egypt, on the pretext of inspecting her properties.
Eupraxia Pharmaceuticals Inc. | 2,937 followers on LinkedIn. Developing Precision Therapies | Eupraxia is a clinical-stage biotechnology company focused on the development of locally delivered ...
Feb 1, 2024 · Decision to proceed with Phase 3 follows completion of End-of-Phase 2 meeting with the U.S. FDA Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology to optimize drug delivery for applications with significant unmet need, today announced the Company has initiated its Phase 3 ...
